Shanghai-based Fosun Pharma has cancelled the proposed acquisition of a 60% stake in OncoCare Cancer Centre, one of the largest private oncology practices in Singapore, according to its filing with the stock exchange.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
